Concord Biotech Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Concord Biotech Share Price

1,505.7052.91 (3.65%)

Closed
As On: 11 Sep, 2026, 03:59 PM IST
As On: 11 Sep, 2026, 03:58 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	1,439.60
High	1,529.00
Low	1,426.90
Prev Close	1,452.80
Volume	3,72,504
VWAP(₹)	1,488.00

Key Metrics

PE Ratio(x)	57.20
EPS - TTM(₹)	26.32
MCap(₹ Cr.)	15,752.06
MCap Rank	39
PB Ratio(x)	7.54
Div Yield(%)	0.50
Face Value(₹)	1.00
52W High(₹)	1,704.00
52W Low(₹)	987.00
MCap/Sales	10.07
Beta(1 Month)	-
BV/Share(₹)	192.62

Concord Biotech Ltd. share price insights

All Debts Paid-off
Company has become debt free for the first time since last 5 years. (Source: Consolidated Financials)
Topline Contraction
Sales de-grew by 11.03%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Candle Formations Yesterday
Long White Candle Bullish Strong Line were formed for Concord Biotech Ltd.
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Concord Biotech Ltd. Share Price Update
Concord Biotech Ltd. share price moved up by 3.65% from its previous close of Rs 1,452.80. Concord Biotech Ltd. stock last traded price is 1,505.70
Share Price Value
Today/Current/Last 1,505.701,510.00
Previous Day 1,452.801,452.60

Found Insights useful?

Concord Biotech Ltd. Share Price Returns

1 Day	3.65%
1 Month	5.37%
3 Months	12.09%
1 Year	-8.12%
3 Years	50.49%
5 Years	N.A.

Concord Biotech Share Recommendations

Mean recosCurrent

BUY

3 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	1	1	1	1
Buy	1	1	1	1
Hold	1	1	1	1
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	3	3	3	3

View all Stock Recommendations

News & Analysis

View all Concord Biotech Share News & Announcements

Financials

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Total Income	270.31	341.43	287.74	260.41	217.67
Total Income Growth (%)	-20.83	18.66	10.50	19.64	-50.45
Total Expenses	193.21	227.09	200.81	176.96	160.37
Total Expenses Growth (%)	-14.92	13.09	13.48	10.35	-36.88
EBIT	77.10	114.34	86.93	83.45	57.30
EBIT Growth (%)	-32.57	31.52	4.17	45.64	-69.06
Profit after Tax (PAT)	58.53	88.79	64.48	63.58	44.06
PAT Growth (%)	-34.09	37.71	1.41	44.31	-68.62
EBIT Margin (%)	28.52	33.49	30.21	32.05	26.32
Net Profit Margin (%)	21.65	26.01	22.41	24.42	20.24
Basic EPS (₹)	5.52	8.46	6.08	6.03	4.21

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Total Income	273.61	341.43	288.22	260.49	217.67
Total Income Growth (%)	-19.86	18.46	10.65	19.67	-50.45
Total Expenses	191.39	223.00	197.86	174.91	160.37
Total Expenses Growth (%)	-14.17	12.70	13.12	9.07	-36.88
EBIT	82.22	118.44	90.36	85.58	57.30
EBIT Growth (%)	-30.57	31.08	5.58	49.35	-69.06
Profit after Tax (PAT)	61.19	90.02	67.78	62.90	42.57
PAT Growth (%)	-32.02	32.81	7.77	47.76	-70.01
EBIT Margin (%)	30.05	34.69	31.35	32.85	26.32
Net Profit Margin (%)	22.37	26.37	23.52	24.15	19.56
Basic EPS (₹)	5.85	8.60	6.48	6.01	4.07

	FY 2026	FY 2025	FY 2024	FY 2023
Total Revenue	1,107.25	1,244.53	1,050.72	888.48
Total Revenue Growth (%)	-11.03	18.45	18.26	20.66
Total Expenses	762.23	748.66	641.53	568.42
Total Expenses Growth (%)	1.81	16.70	12.86	14.79
Profit after Tax (PAT)	260.91	371.64	308.10	240.09
PAT Growth (%)	-29.80	20.62	28.33	37.25
Operating Profit Margin (%)	32.73	41.36	40.48	38.04
Net Profit Margin (%)	24.73	30.96	30.29	28.14
Basic EPS (₹)	24.78	35.52	29.45	22.95

	FY 2026	FY 2025	FY 2024
Total Revenue	1,107.80	1,244.53	1,050.72
Total Revenue Growth (%)	-10.99	18.45	18.26
Total Expenses	753.09	748.66	641.53
Total Expenses Growth (%)	0.59	16.70	12.86
Profit after Tax (PAT)	263.27	372.96	304.73
PAT Growth (%)	-29.41	22.39	27.97
Operating Profit Margin (%)	33.64	41.36	40.48
Net Profit Margin (%)	24.95	31.07	29.96
Basic EPS (₹)	25.17	35.65	29.13

All figures in Rs Cr, unless mentioned otherwise

Insights

Topline Contraction
Sales de-grew by 11.03%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Total Assets	2,234.73	2,034.25	1,700.71	1,513.98
Total Assets Growth (%)	9.86	19.61	12.33	15.33
Total Liabilities	219.59	221.53	174.06	223.98
Total Liabilities Growth (%)	-0.88	27.27	-22.29	6.88
Total Equity	2,015.14	1,812.72	1,526.65	1,290.00
Total Equity Growth (%)	11.17	18.74	18.34	16.93
Current Ratio (x)	7.39	6.17	6.30	3.79
Total Debt to Equity (x)	0.00	0.00	0.00	0.02
Contingent Liabilities	31.60	26.67	26.75	26.59

Annual	FY 2026	FY 2025	FY 2024
Total Assets	2,236.54	2,034.18	1,699.32
Total Assets Growth (%)	9.95	19.71	12.19
Total Liabilities	216.79	221.53	174.06
Total Liabilities Growth (%)	-2.14	27.27	-21.83
Total Equity	2,019.75	1,812.65	1,525.25
Total Equity Growth (%)	11.43	18.84	18.06
Current Ratio (x)	7.45	6.17	6.30
Total Debt to Equity (x)	0.00	0.00	0.00
Contingent Liabilities	31.60	26.67	26.75

All figures in Rs Cr, unless mentioned otherwise

Insights

All Debts Paid-off
Company has become debt free for the first time since last 5 years. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Net Cash flow from Operating Activities	266.88	244.52	265.47	246.00
Net Cash used in Investing Activities	-142.72	-159.99	-154.61	-157.95
Net Cash flow from Financing Activities	-112.88	-98.77	-99.21	-85.22
Net Cash Flow	11.28	-14.24	11.64	2.83
Closing Cash & Cash Equivalent	12.19	0.90	15.14	3.50
Closing Cash & Cash Equivalent Growth (%)	1,247.26	-94.03	332.73	424.70
Total Debt/ CFO (x)	0.00	0.00	0.02	0.13

Annual	FY 2026	FY 2025	FY 2024
Net Cash flow from Operating Activities	263.78	244.52	265.47
Net Cash used in Investing Activities	-142.28	-159.99	-154.61
Net Cash flow from Financing Activities	-114.51	-98.77	-99.21
Net Cash Flow	6.98	-14.24	11.64
Closing Cash & Cash Equivalent	7.89	0.90	15.14
Closing Cash & Cash Equivalent Growth (%)	772.18	-94.03	332.73
Total Debt/ CFO (x)	0.00	0.00	0.02

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 142.72 cr for investing activities which is an YoY decrease of 10.79%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Return on Equity (%)	12.93	20.50	20.18	18.61
Return on Capital Employed (%)	16.71	26.82	26.41	24.54
Return on Assets (%)	11.67	18.26	18.11	15.85
Interest Coverage Ratio (x)	1,482.19	1,040.58	182.35	83.94
Asset Turnover Ratio (x)	0.49	0.64	0.63	0.60
Price to Earnings (x)	40.82	47.39	51.81	-
Price to Book (x)	5.27	9.67	10.43	-
EV/EBITDA (x)	25.28	31.84	34.13	-
EBITDA Margin (%)	39.79	45.89	45.75	44.37

Annual	FY 2026	FY 2025	FY 2024
Return on Equity (%)	13.03	20.57	19.97
Return on Capital Employed (%)	17.15	26.83	26.44
Return on Assets (%)	11.77	18.33	17.93
Interest Coverage Ratio (x)	1,834.47	1,040.58	182.35
Asset Turnover Ratio (x)	0.49	0.64	0.63
Price to Earnings (x)	40.49	47.17	52.36
Price to Book (x)	5.26	9.67	10.44
EV/EBITDA (x)	24.74	31.84	34.13
EBITDA Margin (%)	40.68	45.89	45.75

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
5 Day EMA Crossover
Bullish signal on daily chart
Appeared on: 11 Sep 2026
5D EMA: 1472.76
Last Signal 8 Sep 2026 (Gain 0.63%)
Average price gain of 3.85% within 7 days of Bullish signal in last 5 years
10 Day EMA Crossover
Bullish signal on daily chart
Appeared on: 11 Sep 2026
10D EMA: 1470.59
Last Signal 8 Sep 2026 (Gain 0.63%)
Average price gain of 3.98% within 7 days of Bullish signal in last 5 years
14 Day EMA Crossover
Bullish signal on daily chart
Appeared on: 11 Sep 2026
14D EMA: 1470.98
Last Signal 8 Sep 2026 (Gain 0.63%)
Average price gain of 4.19% within 7 days of Bullish signal in last 5 years
20 Day EMA Crossover
Bullish signal on daily chart
Appeared on: 11 Sep 2026
20D EMA: 1466.86
Last Signal 8 Sep 2026 (Gain 0.63%)
Average price gain of 4.24% within 7 days of Bullish signal in last 5 years
Heikin-Ashi Changeover
Bullish indication on daily chart
Prev. Close Price
1475.30
LTP
1505.70
Formed on: 11 Sep 2026
On daily price chart, Heikin-Ashi candle changed from Red to Green
Price Analysis
42%
Positive Movement
since 1st Jan 2005
on basis
57%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 1547.50 Pivot
1487.20
S1 1445.40
R2 1589.30 S2 1385.10
R3 1691.40 S3 1283.00
Average True Range
5 Days 14 Days 28 Days
55.00 51.85 51.27

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Concord Biotech Ltd.	57.20	7.82	12.93	16.71	11.67	7.53	32.73	24.29	24.78	7.39	0.00	0.00
Glenmark Life	28.23	5.11	16.94	22.51	14.17	5.99	30.65	22.12	45.99	5.21	0.00	0.00
Suven Pharma	158.53	4.17	4.58	5.38	3.12	18.22	12.06	6.61	4.69	2.83	0.04	0.46
Jubilant Life	46.38	2.30	5.61	6.81	2.56	9.61	10.69	4.80	25.15	1.62	0.45	2.62
Alembic Pharma	22.99	2.81	11.89	13.84	7.70	9.28	11.63	9.13	34.33	1.76	0.24	1.74
Add More

Annual Ratios (%)

Choose from Peers

Syngene Int.
Marksans Pharma
Natco Pharma
Indegene
Corona Remedies Ltd.

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 4,61,16,608 44.08 % 0.00
Pledge 0 0.00 % 0.00
FII 78,72,315 7.52 % -0.26
DII 97,91,734 9.37 % 0.15
MF 45,98,027 4.40 % 0.10
Others 4,08,35,547 39.03 % 0.12
QoQ Change
Category Jun 2026 Mar 2026 Dec 2025 Sep 2025
Promoters 44.08 44.08 44.08 44.08
Pledge 0.00 0.00 0.00 0.00
FII 7.52 7.79 7.58 8.03
DII 9.37 9.22 9.57 9.54
Mutual Funds 4.40 4.30 4.44 4.53
Others 39.03 38.91 38.77 38.35

Mutual Funds Ownership

MF Ownership as on 31 July 2026

DSP Small Cap Direct-G
Equity: Small Cap
3
- 189.21
  Amount Invested (in Cr.)
- 0.94%
  % of AUM
- 0.00
  % Change (MoM basis)
SBI Healthcare Opportunities Direct-G
Equity: Sectoral-Pharma
5
- 102.30
  Amount Invested (in Cr.)
- 1.89%
  % of AUM
- 0.00
  % Change (MoM basis)
Edelweiss Small Cap Direct-G
Equity: Small Cap
4
- 80.25
  Amount Invested (in Cr.)
- 1.18%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Concord Biotech Ltd. Top Searches

Corporate Actions

Recent
Board Meeting
Quarterly Results
Jul 28, 2026
General Meeting
-
Jul 07, 2026
Final
755%
May 29, 2026

Announced on	Meeting on
Jul 28, 2026	Jul 31, 2026
Quarterly Results
May 25, 2026	May 29, 2026
Audited Results & Final Dividend
Feb 06, 2026	Feb 11, 2026
Quarterly Results
Nov 10, 2025	Nov 13, 2025
Quarterly Results
Aug 04, 2025	Aug 08, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 29, 2026 Jul 24, 2026 755%
May 29, 2025 Sep 03, 2025 1070%
May 23, 2024 Jun 21, 2024 875%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jul 07, 2026 Jul 31, 2026
-
Aug 13, 2025 Sep 09, 2025
-
Jun 14, 2024 Jun 29, 2024
Book closure from Jun 23, 2024 to Jun 29, 2024

About Concord Biotech

Concord Biotech Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 15,752.06 Crore) operating in Pharmaceuticals sector.

Concord Biotech Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Other Operating Revenue and Sale of services for the year ending 31-Mar-2025.

For the quarter ended 30-06-2026, the company has reported a Consolidated Total Income of Rs 270.31 Crore, down 20.83 % from last quarter Total Income of Rs 341.43 Crore and up 24.19 % from last year same quarter Total Income of Rs 217.67 Crore. Company has reported net profit after tax of Rs 56.42 Crore in latest quarter.

The company’s top management includes Mr.Sudhir Vaid, Mr.Ankur Vaid, Mr.Rajiv Ambrish Agarwal, Mr.Ravi Kapoor, Mr.Amitabh Thakore, Mr.Arvind Agarwal, Mrs.Bharti Khanna, Mr.Jayaram Easwaran, Mr.Mandayam Chakravarthy Sriraman, Mr.Raviraj Karia, Mr.Paritosh Trivedi. Company has B S R & Co. LLP as its auditors. As on 30-06-2026, the company has a total of 10.46 Crore shares outstanding.

Concord Biotech Ltd. Share Price Today is Rs. 1505.70. On previous day, the Concord Biotech Ltd. Share Price (NSE) closed at Rs. 1452.8, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 30th Jun, 2026, the promoter held 44.08% of the stake in Concord Biotech Ltd. shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Concord Biotech Ltd. stocks was 7.53% as compared to 7.79% in Mar 2026 with decrease of 0.26%. The domestic institutional investors (DII) holdings on 30th Jun, 2026 was 9.37% as compared to 9.22% in Mar 2026 with increase of 0.15%. Out of the total DII holdings in Concord Biotech Ltd. shares 4.4% was held by mutual funds. The rest including public held is 39.02%. Concord Biotech Ltd. stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Concord Biotech Ltd. Dividend: Ever since 1984, Concord Biotech Ltd. dividends has been paid out around 3 times. As on 11 Sep, 2026, 03:59 PM IST, The overall dividend yield for Concord Biotech Ltd. stands at 0.5%. The last dividend paid was on July 24, 2026 (Rs. 7.55). The Earnings Per Share (EPS) for quarter ending 30th Jun 2026 is Rs. 26.32.

Concord Biotech Ltd. Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 270.31 Cr. of sales and 0.0% of quarterly net null, there have been multiple ups and downs in the Concord Biotech Ltd. stock prices in the past few weeks. For example, Concord Biotech Ltd. stock price on 4th of September 2026 was around Rs. 1417.1. Concord Biotech Ltd. share price now stands at an average of Rs. 1505.70. Judging by last week's performance, stock is in up trend.

Concord Biotech Ltd. has a median target price of Rs. 1506.0 in 12 months by 3 analysts. They have provided a high estimate of Rs. 1700.0 and low estimate of Rs. 1268.0 for Concord Biotech Ltd. share.

Historical Prices and Performance:
Concord Biotech Ltd., incorporated in 1984 is a Mid Cap company (with a market cap of Rs. 15762.0) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Concord Biotech Ltd. stock was 12.93%, 20.5%, 20.18%, 18.61% and 15.85% respectively.
The Concord Biotech Ltd. share gave a 3 year return of 50.49% as compared to Nifty 50 which gave a return of 17.01%.
Concord Biotech Ltd. announced 755.0% final dividend on July 24, 2026.

Key Metrics:
PE Ratio of Concord Biotech Ltd. is 57.2
Prices/Sales Ratio of Concord Biotech Ltd. is 10.07
Price/Book Ratio of Concord Biotech Ltd. is 7.82

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Concord Biotech Ltd., major competitors and peers include Glenmark Life, Suven Pharma, Jubilant Life and Alembic Pharma. As of Mar 2026, the dividend yield of Concord Biotech Ltd. stands at 0.5% while Glenmark Life, Suven Pharma, Jubilant Life and Alembic Pharma stand at 0.0%, 0.0%, 0.49% and 1.48% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 57.2 and 7.82 respectively.

Leadership of Concord Biotech Ltd. :
Paritosh Trivedi is Co. Secretary & Compl. Officer
Raviraj Karia is Chief Financial Officer
Devang Bhatt is Vice President - Sales & Marketing
Manoj Kumar is Vice President
Sundeep Bengani is General Manager
Sudhir Vaid is Chairman & Managing Director
Ankur Vaid is Joint Managing Director & CEO
Ravi Kapoor is Non Executive Director
Rajiv Ambrish Agarwal is Non Executive Director
Bharti Khanna is Independent Director
Amitabh Thakore is Independent Director
Arvind Agarwal is Independent Director
Jayaram Easwaran is Independent Director
Mandayam Chakravarthy Sriraman is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty 500, BSE 500, BSE 250 SmallCap Index, BSE SmallCap, BSE Healthcare

Address

1482-1486, Trasad Road,Dholka,Ahmedabad, Gujarat - 382225

Contact

complianceofficer@concordbiotech.com

http://www.concordbiotech.com

Executive Leadership

SV

Sudhir Vaid

Chairman & Managing Director

AV

Ankur Vaid

Joint Managing Director & CEO

RA

Rajiv Ambrish Agarwal

Non Executive Director

RK

Ravi Kapoor

Non Executive Director

Show More

Auditors

B S R & Co. LLP

Deloitte Haskins & Sells

FAQs about Concord Biotech share

1. What is Concord Biotech Ltd. share price and what are the returns for Concord Biotech Ltd. share?
Concord Biotech Ltd. share price is Rs 1,505.70 as on 11 Sep, 2026, 03:59 PM IST. Concord Biotech Ltd. share price is up by 3.65% based on previous share price of Rs 1,464.5. Concord Biotech Ltd. share price trend:
- Last 3 Years: Concord Biotech Ltd. Share price moved up by 50.49%
2. What are the returns for Concord Biotech Ltd. share?
Return Performance of Concord Biotech Ltd. Shares:
- 1 Week: Concord Biotech Ltd. share price moved up by 6.25%
3. What has been highest price of Concord Biotech Ltd. share in last 52 weeks?
52 Week high of Concord Biotech Ltd. share is Rs 1,704.00 while 52 week low is Rs 987.00
4. What is the PE & PB ratio of Concord Biotech Ltd.?
The PE ratio of Concord Biotech Ltd. stands at 55.19, while the PB ratio is 7.54.
5. What's the market capitalization of Concord Biotech Ltd.?
Concord Biotech Ltd. share has a market capitalization of Rs 15,752.06 Cr. Within Pharmaceuticals sector, it's market cap rank is 39.

Top Gainers

As on 03:59 PM | 11 Sep 2026

1,656.00

1342.20 (427.72%)

3,383.70

2280.90 (206.83%)

Syrma SGS Technology

1,589.30

1060.30 (200.43%)

1,969.00

1302.25 (195.31%)

2,676.60

1752.10 (189.52%)

Top Losers

As on 04:08 PM | 11 Sep 2026

Tata Investment

650.90

-6233.10 (-90.54%)

305.00

-2712.60 (-89.89%)

711.00

-3361.70 (-82.54%)

2,548.20

-10748.80 (-80.84%)

419.00

-1707.80 (-80.30%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.